JP6224611B2 - 三次元の組織培養およびティッシュエンジニアリングのためのグルコマンナンスキャフォールド - Google Patents
三次元の組織培養およびティッシュエンジニアリングのためのグルコマンナンスキャフォールド Download PDFInfo
- Publication number
- JP6224611B2 JP6224611B2 JP2014544866A JP2014544866A JP6224611B2 JP 6224611 B2 JP6224611 B2 JP 6224611B2 JP 2014544866 A JP2014544866 A JP 2014544866A JP 2014544866 A JP2014544866 A JP 2014544866A JP 6224611 B2 JP6224611 B2 JP 6224611B2
- Authority
- JP
- Japan
- Prior art keywords
- glucomannan
- scaffold
- cells
- glucomannan scaffold
- medium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0068—General culture methods using substrates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0087—Glucomannans or galactomannans; Tara or tara gum, i.e. D-mannose and D-galactose units, e.g. from Cesalpinia spinosa; Tamarind gum, i.e. D-galactose, D-glucose and D-xylose units, e.g. from Tamarindus indica; Gum Arabic, i.e. L-arabinose, L-rhamnose, D-galactose and D-glucuronic acid units, e.g. from Acacia Senegal or Acacia Seyal; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/28—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof by elimination of a liquid phase from a macromolecular composition or article, e.g. drying of coagulum
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/36—After-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0662—Stem cells
- C12N5/0663—Bone marrow mesenchymal stem cells (BM-MSC)
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2201/00—Foams characterised by the foaming process
- C08J2201/04—Foams characterised by the foaming process characterised by the elimination of a liquid or solid component, e.g. precipitation, leaching out, evaporation
- C08J2201/048—Elimination of a frozen liquid phase
- C08J2201/0484—Elimination of a frozen liquid phase the liquid phase being aqueous
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2207/00—Foams characterised by their intended use
- C08J2207/10—Medical applications, e.g. biocompatible scaffolds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2305/00—Characterised by the use of polysaccharides or of their derivatives not provided for in groups C08J2301/00 or C08J2303/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Materials Engineering (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Developmental Biology & Embryology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Dermatology (AREA)
- Materials For Medical Uses (AREA)
Description
本出願は2011年11月29日に出願された米国仮特許出願第61/564,553号に基づく優先権を主張し、同仮特許出願の全文が、あらゆる目的のため本明細書に組み込まれる。
I.定義
本明細書中、用語「グルコマンナン」はD−グルコースとD−マンノースとが約1:1.6の割合でβ−1,4結合した構造に約11残基間隔で側鎖を有する天然由来の多糖(Alonso−Sande et al. Eur J Pharm Biopharm. 2009 72:453〜462)およびその誘導体を意味する。グルコマンナンは約5〜10%が置換されたアセチル基からなる主鎖を有しており、これらのアセチル基は水素結合および可溶性を与える疎水性相互作用に関与している。グルコマンナン誘導体の例としてはO−アルキル誘導体やO−カルボキシアルキル誘導体といった水溶性誘導体、置換度が様々に異なる誘導体(5〜10%超または未満のアセチル基が置換されているなど)、酸化度が様々に異なる誘導体、グラフト共重合体(アクリレート・アクリルアミド共重合体など)とその塩(第四級アンモニウム塩など)が挙げられるが、これらに限定されない。
II.中和グルコマンナンスキャフォールド
III.細胞の増殖
IV.実施例
実施例1:グルコマンナンスキャフォールドの作製
グルコマンナンスキャフォールドの中和
実施例2:中和グルコマンナンスキャフォールド上での細胞増殖
実施例3:酵素消化
実施例4:骨芽細胞分化
Claims (23)
- 中和グルコマンナンスキャフォールドを作製する方法であって、pHが約8を超える塩基性グルコマンナンスキャフォールドを大気圧を超える気圧で水溶液と接触させてpHが約7である中和グルコマンナンスキャフォールドを形成することにより前記中和グルコマンナンスキャフォールドを作製することを含む、方法。
- 前記接触が0℃〜130℃の温度で行われる、請求項1に記載の方法。
- 前記接触が20℃〜50℃の温度で行われる、請求項1に記載の方法。
- 前記接触が約37℃の温度で行われる、請求項1の方法。
- 前記接触が0.1psi〜50psiだけ大気圧を超える圧力で行われる、請求項1に記載の方法。
- 前記接触が1分〜1ヵ月の期間行われる、請求項1に記載の方法。
- 前記接触が1時間〜1週間の期間行われる、請求項1に記載の方法。
- 前記接触が1時間〜1日の期間行われる、請求項1に記載の方法。
- 前記接触が8時間〜20時間の期間行われる、請求項1に記載の方法。
- 前記塩基性グルコマンナンスキャフォールドは細胞接着促進剤をさらに含有する、請求項1に記載の方法。
- 前記細胞接着促進剤がポリ−L−リシン(PLL)、ポリ−D−リシン(PDL)、RGDペプチド(RGD)、KQAGDV、VAPG、FGL、アミン基、フィブロネクチン、エラスチン、コラーゲンおよびラミニンからなる群から選択される、請求項10に記載の方法。
- 前記細胞接着促進剤がポリ−L−リシン(PLL)である、請求項11に記載の方法。
- 前記方法が、
グルコマンナン粉末、前記細胞接着促進剤、アルカリ性溶液および水を含有する反応混合物を生成することと、
前記反応混合物を50℃〜130℃の温度で加熱してグルコマンナンゲルを形成する工程と、
前記グルコマンナンゲルの圧力を、0.1psi〜200psiだけ大気圧を超える圧力に上昇させることと、
前記グルコマンナンゲルを50℃未満の温度まで冷却することと、
前記グルコマンナンゲルから前記水を除去して前記塩基性グルコマンナンゲルを形成することと
をさらに含む、請求項10に記載の方法。 - 前記圧力が14.7psiから50psiに上昇される、請求項13に記載の方法。
- 前記除去工程が昇華によって行われる、請求項13に記載の方法。
- 前記水溶液が水、緩衝液、酸性溶液および細胞培養培地からなる群から選択される、請求項1に記載の方法。
- 前記水溶液が緩衝液である、請求項1に記載の方法。
- 前記緩衝液がPBS、HEPES、MES、MOPS、TRISおよびBIS−TRISプロパンからなる群から選択される、請求項17に記載の方法。
- 前記緩衝液がPBSである、請求項17に記載の方法。
- 前記水溶液が細胞培養培地である、請求項1に記載の方法。
- 前記細胞培養培地がロズウェルパーク記念研究所培地(RPMI)、ダルベッコ変法イーグル培地(DMEM)、最小必須培地(MEM)、ダルベッコ変法イーグル培地:混合栄養F−12培地(DMEM/F12)、イスコフ変法ダルベッコ培地(IMDM)、National Collection of Type Cultures培地(NCTC)および骨芽細胞分化誘導培地(OIM)からなる群から選択される、請求項20に記載の方法。
- 中和グルコマンナンスキャフォールド上で細胞を増殖させる方法であって、
pHが約8を超える塩基性グルコマンナンスキャフォールドを大気圧を超える気圧で水溶液と接触させてpHが約7である中和グルコマンナンスキャフォールドを形成することにより前記中和グルコマンナンスキャフォールドを作製する工程、及び前記中和グルコマンナンスキャフォールドと細胞との反応混合物を前記細胞が増殖するよう加熱することにより前記中和グルコマンナンスキャフォールド上で細胞を増殖させることを含む、方法。 - 前記細胞が体細胞、幹細胞または前駆細胞およびこれらの細胞から誘導される細胞からなる群から選択される、請求項22に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161564553P | 2011-11-29 | 2011-11-29 | |
US61/564,553 | 2011-11-29 | ||
PCT/US2012/066982 WO2013082239A1 (en) | 2011-11-29 | 2012-11-29 | Glucomannan scaffolding for three-dimensional tissue culture and engineering |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017112950A Division JP2017205113A (ja) | 2011-11-29 | 2017-06-07 | 三次元の組織培養およびティッシュエンジニアリングのためのグルコマンナンスキャフォールド |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2015502746A JP2015502746A (ja) | 2015-01-29 |
JP2015502746A5 JP2015502746A5 (ja) | 2015-05-07 |
JP6224611B2 true JP6224611B2 (ja) | 2017-11-01 |
Family
ID=48536036
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014544866A Active JP6224611B2 (ja) | 2011-11-29 | 2012-11-29 | 三次元の組織培養およびティッシュエンジニアリングのためのグルコマンナンスキャフォールド |
JP2017112950A Withdrawn JP2017205113A (ja) | 2011-11-29 | 2017-06-07 | 三次元の組織培養およびティッシュエンジニアリングのためのグルコマンナンスキャフォールド |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017112950A Withdrawn JP2017205113A (ja) | 2011-11-29 | 2017-06-07 | 三次元の組織培養およびティッシュエンジニアリングのためのグルコマンナンスキャフォールド |
Country Status (10)
Country | Link |
---|---|
US (2) | US9359591B2 (ja) |
EP (1) | EP2785830B1 (ja) |
JP (2) | JP6224611B2 (ja) |
KR (1) | KR102120629B1 (ja) |
CN (1) | CN103958666B (ja) |
CA (1) | CA2857283C (ja) |
ES (1) | ES2681443T3 (ja) |
HK (1) | HK1202889A1 (ja) |
MX (1) | MX353512B (ja) |
WO (1) | WO2013082239A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6104312B2 (ja) * | 2014-06-19 | 2017-03-29 | 日東電工株式会社 | 組織再生促進剤 |
BR102015031933B1 (pt) * | 2015-12-18 | 2021-05-25 | Universidade Estadual De Campinas - Unicamp | processo de obtenção de membranas assimétricas, membranas assim obtidas e uso |
CN109745582B (zh) * | 2019-03-11 | 2021-11-19 | 西南科技大学 | 一种白芨多糖复合细胞支架的制备方法 |
WO2021086862A1 (en) * | 2019-10-29 | 2021-05-06 | Anemorix, LLC | Porous glucomannan scaffolds and methods for producing the scaffolds |
WO2023105878A1 (ja) * | 2021-12-09 | 2023-06-15 | 日東電工株式会社 | 多孔体及びその製造方法 |
CN115671381B (zh) * | 2022-11-07 | 2023-09-12 | 南京市口腔医院 | 具有免疫调节活性的骨再生材料及其制备方法和应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS59169462A (ja) * | 1983-03-14 | 1984-09-25 | Kazuhiro Sarui | こんにやくの処理法 |
CA2221195A1 (en) | 1997-11-14 | 1999-05-14 | Chantal E. Holy | Biodegradable polymer matrix |
IL144446A0 (en) | 2001-07-19 | 2002-05-23 | Prochon Biotech Ltd | Plasma protein matrices and methods for their preparation |
CN1259980C (zh) * | 2003-11-27 | 2006-06-21 | 四川大学 | 一种生物医用材料及其制备方法和用途 |
JP4526851B2 (ja) * | 2004-03-31 | 2010-08-18 | 明彦 谷岡 | 多糖類のナノスケールの繊維および成形体 |
US8303972B2 (en) | 2005-04-19 | 2012-11-06 | Advanced Cardiovascular Systems, Inc. | Hydrogel bioscaffoldings and biomedical device coatings |
US20060292690A1 (en) * | 2005-06-22 | 2006-12-28 | Cesco Bioengineering Co., Ltd. | Method of making cell growth surface |
CN100431624C (zh) * | 2005-12-07 | 2008-11-12 | 浙江大学 | 可注射聚乳酸微载体/壳聚糖水凝胶复合支架的制备方法 |
CA2701323C (en) * | 2007-10-04 | 2016-10-18 | Ultraceuticals R & D Pty Ltd | Compositions of glucomannan cross-linked with hyaluronic acid for dermal regeneration |
CN101322858B (zh) * | 2008-07-14 | 2013-06-12 | 昆明理工大学 | 一种引导骨组织再生修复的可降解多孔支架材料及其制备方法 |
CN101322857B (zh) * | 2008-07-14 | 2013-04-10 | 昆明理工大学 | 一种复合骨组织工程多孔支架材料及其制备方法 |
JP2010245133A (ja) * | 2009-04-01 | 2010-10-28 | Nippon Chemicon Corp | ゲル電解質及びその製造方法、このゲル電化質を用いた電気化学素子 |
-
2012
- 2012-11-29 CN CN201280058878.XA patent/CN103958666B/zh active Active
- 2012-11-29 US US14/360,910 patent/US9359591B2/en active Active
- 2012-11-29 ES ES12853122.5T patent/ES2681443T3/es active Active
- 2012-11-29 EP EP12853122.5A patent/EP2785830B1/en active Active
- 2012-11-29 CA CA2857283A patent/CA2857283C/en active Active
- 2012-11-29 KR KR1020147014570A patent/KR102120629B1/ko active IP Right Grant
- 2012-11-29 WO PCT/US2012/066982 patent/WO2013082239A1/en active Application Filing
- 2012-11-29 MX MX2014006371A patent/MX353512B/es active IP Right Grant
- 2012-11-29 JP JP2014544866A patent/JP6224611B2/ja active Active
-
2015
- 2015-04-01 HK HK15103335.1A patent/HK1202889A1/xx unknown
-
2016
- 2016-05-31 US US15/169,521 patent/US9926528B2/en active Active
-
2017
- 2017-06-07 JP JP2017112950A patent/JP2017205113A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
CA2857283C (en) | 2021-04-27 |
EP2785830A1 (en) | 2014-10-08 |
US20170029764A1 (en) | 2017-02-02 |
CN103958666A (zh) | 2014-07-30 |
JP2017205113A (ja) | 2017-11-24 |
WO2013082239A1 (en) | 2013-06-06 |
CN103958666B (zh) | 2020-01-10 |
ES2681443T3 (es) | 2018-09-13 |
MX2014006371A (es) | 2014-09-22 |
US20140315308A1 (en) | 2014-10-23 |
EP2785830A4 (en) | 2015-09-02 |
JP2015502746A (ja) | 2015-01-29 |
CA2857283A1 (en) | 2013-06-06 |
US9359591B2 (en) | 2016-06-07 |
KR20140103931A (ko) | 2014-08-27 |
MX353512B (es) | 2018-01-17 |
US9926528B2 (en) | 2018-03-27 |
EP2785830B1 (en) | 2018-06-20 |
KR102120629B1 (ko) | 2020-06-09 |
HK1202889A1 (en) | 2015-10-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2017205113A (ja) | 三次元の組織培養およびティッシュエンジニアリングのためのグルコマンナンスキャフォールド | |
Stratesteffen et al. | GelMA-collagen blends enable drop-on-demand 3D printablility and promote angiogenesis | |
Georgopoulou et al. | Chitosan/gelatin scaffolds support bone regeneration | |
Kim et al. | Bioactive cell-derived matrices combined with polymer mesh scaffold for osteogenesis and bone healing | |
Bidarra et al. | Injectable alginate hydrogels for cell delivery in tissue engineering | |
TWI258372B (en) | Use of a device in manufacture of a medical product, a method of producing a device for repairing diseased or damaged tissue in a subject, and a device having tissue-like characteristics | |
Garcia Cruz et al. | Differentiation of mesenchymal stem cells in chitosan scaffolds with double micro and macroporosity | |
Yin et al. | Controlled release of FGF-2 and BMP-2 in tissue engineered periosteum promotes bone repair in rats | |
SG185279A1 (en) | Method for preparing porous scaffold for tissue engineering, cell culture and cell delivery | |
Deng et al. | Peptide-decorated nanofibrous niche augments in vitro directed osteogenic conversion of human pluripotent stem cells | |
Thein‐Han et al. | Chitosan scaffolds for in vitro buffalo embryonic stem‐like cell culture: An approach to tissue engineering | |
Yadav et al. | In vitro chondrogenesis with lysozyme susceptible bacterial cellulose as a scaffold | |
Kusuma et al. | Transferable matrixes produced from decellularized extracellular matrix promote proliferation and osteogenic differentiation of mesenchymal stem cells and facilitate scale-up | |
Korurer et al. | Production of a composite hyaluronic acid/gelatin blood plasma gel for hydrogel‐based adipose tissue engineering applications | |
Svobodová et al. | Poly (amino acid)‐based fibrous scaffolds modified with surface‐pendant peptides for cartilage tissue engineering | |
Landau et al. | Human-engineered auricular reconstruction (hEAR) by 3D-printed molding with human-derived auricular and costal chondrocytes and adipose-derived mesenchymal stem cells | |
JP2016525541A (ja) | 球状軟骨細胞治療剤の製造方法 | |
Rogina et al. | Characterization of chitosan-based scaffolds seeded with sheep nasal chondrocytes for cartilage tissue engineering | |
Cordonnier et al. | Osteoblastic differentiation and potent osteogenicity of three‐dimensional hBMSC‐BCP particle constructs | |
Kumbhar et al. | Self-functionalized, oppositely charged chitosan-alginate scaffolds for biomedical applications | |
Higuchi et al. | Temperature‐induced cell detachment on immobilized pluronic surface | |
Morgan et al. | Formation of a human-derived fat tissue layer in PDLLGA hollow fibre scaffolds for adipocyte tissue engineering | |
WO2004082728A1 (ja) | 医用材料 | |
Wei et al. | Hydrogels to Support Transplantation of Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial Cells | |
Zhou et al. | Microspheres for cell culture |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151120 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160712 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160713 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161012 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170607 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170713 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170912 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20171005 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6224611 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |